Sacubitril

Drug Profile

Sacubitril

Alternative Names: AHU-377

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Biphenyl compounds; Esters; Pentanoic acids; Small molecules
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Essential hypertension

Most Recent Events

  • 31 Dec 2011 Novartis completes a phase II trial in Essential hypertension in USA, Argentina, Canada, Hungary, Romania, Slovakia, Spain, South Korea & India (NCT01281306)
  • 17 Oct 2011 Novartis completes enrolment in its phase II trial for Hypertension in the US, Argentina, Canada, Asia and the EU (NCT01281306)
  • 17 Oct 2011 Phase-II clinical trials in Essential hypertension in Romania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top